Coherus Oncology, Inc. (CHRS) › Cash & EquivalentsCoherus Oncology, Inc. (CHRS) — Cash & EquivalentsAnnual figures by period end, from SEC filings.2011-12-31: $7.68M2012-12-31: $14.55M2013-12-31: $39.55M2014-12-31: $150.39M2015-12-31: $158.23M2016-12-31: $124.95M2017-12-31: $126.91M2018-12-31: $72.36M2019-12-31: $177.67M2020-12-31: $541.16M2021-12-31: $417.19M2022-12-31: $63.55M2023-12-31: $102.89M2024-12-31: $125.99M2025-12-31: $88.88M$88.88M2011-12-31Cash & Equivalents (USD)2025-12-31Period endedCash & EquivalentsChange YoYSource filing2025-12-31$88.88M-29.5%2026-03-09Balance as of period end2024-12-31$125.99M+22.4%2026-03-09Balance as of period end2023-12-31$102.89M+61.9%2025-03-17Balance as of period end2022-12-31$63.55M-84.8%2025-03-17Balance as of period end2021-12-31$417.19M-22.9%2025-03-17Balance as of period end2020-12-31$541.16M+204.6%2024-03-15Balance as of period end2019-12-31$177.67M+145.5%2023-03-06Balance as of period end2018-12-31$72.36M-43.0%2022-02-23Balance as of period end2017-12-31$126.91M+1.6%2020-02-27Balance as of period end2016-12-31$124.95M-21.0%2018-03-08Balance as of period end2015-12-31$158.23M+5.2%2018-03-08Balance as of period end2014-12-31$150.39M+280.2%2018-03-08Balance as of period end2013-12-31$39.55M+171.9%2017-03-14Balance as of period end2012-12-31$14.55M+89.3%2016-02-29Balance as of period end2011-12-31$7.68M—2015-03-23Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)